CTOs on the Move

Immunocellular Therapeutics (Fka: Optical Molecu

www.imuc.com

 
Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imuc.com
  • 21900 Burbank Blvd Fl 3
    Woodland Hills, CA USA 91367
  • Phone: 818.992.2907

Executives

Name Title Contact Details

Similar Companies

Seven Bridges

Personalized medicine, drug discovery, diagnostic testing, and foundational genomic research all start with bioinformatics. The world`s largest research institutions use Seven Bridges` software platform to help them analyze, store, and act on genomic and other biological data.

Molecular Assemblies

At Molecular Assemblies, we are enabling the next era in biotechnology through a completely new approach to DNA synthesis utilizing natural processes. We are developing a platform-independent, scalable DNA synthesis technology designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably.

Medivant Healthcare

Uniquely poised as a world class FDA registered outsourcing pharmaceutical manufacturer, Medivant offers the best in the industry when it comes to reliability and management, supply chain transparency, and lower total net cost. *dba Tailstorm Health, Inc. Our vials are made to the exact dosage specification allowing you to achieve a lower net cost of ordering, reducing total waste, and saving you money in the process. Our state of the art manufacturing facility has been completely designed from the ground up with the highest technology available, with full automation, and superior excellence, with highly trained staff experienced in top quality production.

MicroDose Therapeutx

MicroDose Therapeutx is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glyscend

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.